Kavli Affiliate: Seth Blackshaw
| Authors: Clayton P. Santiago, Megan Y. Gimmen, Yuchen Lu, Minda M. McNally, Leighton H. Duncan, Tyler Creamer, Linda Orzolek, Seth Blackshaw and Mandeep Singh
| Summary:
Structured Abstract Purpose Proliferative vitreoretinopathy (PVR) is the most common cause of failure of retinal reattachment surgery and the molecular changes leading to this aberrant wound healing process is currently unknown. We aimed to study PVR pathogenesis using single-cell transcriptomics to dissect cellular heterogeneity in a rabbit PVR model. Methods PVR was induced unilaterally in Dutch Belted rabbits. At different timepoints following PVR induction, retinas were dissociated into either cells or nuclei suspension and processed for single-cell or single-nucleus RNA sequencing (scRNA-seq or snRNA-seq). Results scRNA-Seq and snRNA-Seq were conducted on retinas at 4 hours and 14 days after disease induction. While the capture rate of unique molecular identifiers (UMI) and genes were greater in scRNA-seq samples, overall gene expression profiles of individual cell types were highly correlated between scRNA-seq and snRNA-seq. A major disparity between the two sequencing modalities is the cell type capture rate, however, with glial cell types over-represented in scRNA-seq, and inner retinal neurons were enriched by snRNA-seq. Furthermore, fibrotic Müller glia were over-represented in snRNA-seq samples, while reactive Müller glia were in scRNA-seq samples. Trajectory analyses were similar between the two methods, allowing for the combined analysis of the scRNA-seq and snRNA-seq datasets. Conclusions These findings highlight limitations of both scRNA-seq and snRNA-seq analysis and imply that use of both techniques can more accurately identify transcriptional networks critical for aberrant fibrogenesis in PVR. Competing Interest Statement S. Blackshaw has received research support from Genentech, is a co-founder of, and shareholder in CDI Labs, LLC; and is/was a consultant for Third Rock Ventures and Tenpoint Therapeutics. M.S Singh has received research support from Bayer and is/was a consultant for Revision Therapeutics, Johnson & Johnson, Bayer AG, Novartis Pharmaceuticals, W. L. Gore & Associates, Kala Pharmaceuticals, and Acucela.